Dr. Gray Kueberuwa, DPhil, EMBA

Chief Executive Officer

Gray leads ImmunoKey’s corporate strategy and the development of CARKey™, a next-generation CAR T-cell platform designed to address tumour heterogeneity, off-tumour toxicity and other barriers that have limited the effectiveness of cell therapies in solid cancers.

He holds a master’s degree in Biochemistry and a DPhil in oncolytic virotherapy from the University of Oxford, together with an Executive MBA from Quantic School of Business and Technology. This combination of scientific and business training underpins his approach to translating differentiated technologies into investable and clinically relevant therapeutic programmes.

Gray has more than a decade of experience across the cell therapy development pathway, spanning discovery research, intellectual property strategy, process development, GMP lentiviral vector and cell therapy manufacturing, regulatory submissions to the MHRA and FDA, clinical operations and clinical logistics. He has established research facilities, built multidisciplinary teams and held strategic leadership responsibilities during the development, acquisition and subsequent international expansion of a cell therapy biotechnology company.